HIGH DOSE CHEMOTHERAPY AND COMBINATION ANTI-HIV THERAPY FOR HIV ASSOCIATED HO

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine whether peripheral blood progenitor cells (immature cells that can become blood cells) can be collected from patients with HIV infection who are being treated with combination anti-HIV therapy. These cells will be given back to research participants after high dose chemotherapy for non-Hodgkin's lymphoma (NHL) or Hodgkin's Disease (HD). Additional purposes are to evaluate the side effects of this treatment and estimate the disease-free and overall survival. The prognosis of patients with HIV-related NHL/HD is very poor with conventional chemotherapy and/or radiotherapy. Although remission (absence of detectable lymphoma) can be achieved, the duration of remission usually is short. Recent studies have shown that persons who have NHL/HD but no HIV infection who receive high dose chemotherapy in an effort to destroy any remaining NHL/HD can achieve long-term remission. However, this type of intensive therapy also destroys normal marrow cells. To help reduce this problem, the patient's peripheral blood progenitor cells (PBPC) can be collected part way through chemotherapy to be returned to the subject intravenously (through a vein) after the intensive therapy is over. This procedure is called autologous PBPC transplantation.